A Phase 1 Study of [225Ac]-FPI-1434 Injection

Official Title

A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients With Advanced Solid Tumours

Summary:

The primary objectives are to: 1. Evaluate the safety and tolerability of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection in patients with advanced refractory solid tumours 2. Determine the maximum tolerated dose of a single [225Ac]-FPI-1434 Injection The secondary objectives are to: 1. Obtain preliminary data on tumour uptake of [111In]-FPI-1547 Injection in cancer patients 2. Determine the dosimetry of [111In]-FPI-1547 Injection (whole body and individual organs) 3. Determine the pharmacokinetics of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection 4. Estimate the dosimetry for [225Ac]-FPI-1434 Injection (whole body and individual regions) 5. Describe efficacy of [225Ac]-FPI-1434 Injection 6. Assess the effect of [225Ac]-FPI-1434 Injection on the QTc interval 7. Assess changes in human growth hormone (hGh), insulin-like growth factor (IGF)-1 and insulin-like growth binding protein 3 (IGFBP-3) following [111In]-FPI-1547 and [225Ac]-FPI-1434 injections

Trial Description

Primary Outcome:

  • Frequency and severity of adverse events
Secondary Outcome:
  • Tumour uptake of [111In]-FPI-1547 Injection in selected regions of interest on SPECT/CT images.
  • Radiation doses for selected organs and whole body both for [111In]-FPI-1547 and [225Ac]-FPI-1434.
  • Radiation doses for tumour lesions for [225Ac]-FPI-1434.
  • Clearance for radioactivity and for the targeting antibody.
  • Area under the curve (AUC) for radioactivity and for the targeting antibody.
  • Cmax for radioactivity and for the targeting antibody.
  • Half-life for radioactivity and for the targeting antibody.
  • Objective response rate (sum of complete and partial response) per RECIST 1.1 or PCWG3 guidelines, duration of response and progression free survival.
  • Changes in the QTc interval in milliseconds after [225Ac]-FPI-1434 treatment, compared to baseline.
  • Changes in human growth hormone (hGh), insulin-like growth factor (IGF)-1 and insulin-like growth binding protein 3 (IGFBP-3) following [111In]-FPI-1547 and [225Ac]-FPI-1434 injections.
This is a first-in-human Phase 1, non-randomized, multi-centre, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection and to establish the maximum tolerated dose of a single [225Ac]-FPI-1434 Injection in patients with solid tumours with demonstrated tumour uptake of [111In]-FPI-1547.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society